These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 25434634)

  • 61. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.
    Mulier S; Claes JP; Dierieck V; Amiel JO; Pahaut JP; Marcelis L; Bastin F; Vanderbeeken D; Finet C; Cran S; Velu T
    Curr Pharm Des; 2012; 18(25):3793-803. PubMed ID: 22591422
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model.
    Bespalov VG; Kireeva GS; Belyaeva OA; Kalinin OE; Senchik KY; Stukov AN; Gafton GI; Guseynov KD; Belyaev AM
    J Surg Oncol; 2016 Mar; 113(4):438-42. PubMed ID: 26710749
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.
    Pavlov MJ; Kovacevic PA; Ceranic MS; Stamenkovic AB; Ivanovic AM; Kecmanovic DM
    Eur J Surg Oncol; 2009 Nov; 35(11):1186-91. PubMed ID: 19356887
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
    Helm CW
    Oncologist; 2009 Jul; 14(7):683-94. PubMed ID: 19608639
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
    Helm CW; Randall-Whitis L; Martin RS; Metzinger DS; Gordinier ME; Parker LP; Edwards RP
    Gynecol Oncol; 2007 Apr; 105(1):90-6. PubMed ID: 17173957
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome.
    Fagotti A; Costantini B; Vizzielli G; Perelli F; Ercoli A; Gallotta V; Scambia G; Fanfani F
    Gynecol Oncol; 2011 Aug; 122(2):221-5. PubMed ID: 21543112
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Introducing Hyperthermic Intraperitoneal Chemotherapy into Gynecological Oncology Practice - Feasibility and Safety Considerations: Single-Center Experience.
    Abramian A; Zivanovic O; Kuhn W; Weber S; Schaefer N; Keyver-Paik MD; Kiefer N
    Oncol Res Treat; 2016; 39(4):178-84. PubMed ID: 27160457
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis.
    Wong JF; Tan GH; Wang W; Soo KC; Teo MC
    World J Surg; 2015 Jun; 39(6):1578-83. PubMed ID: 25651962
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence.
    Cianci S; Ronsini C; Vizzielli G; Tropea A; Biondi A; Scambia G; Fagotti A
    Updates Surg; 2019 Jun; 71(2):389-394. PubMed ID: 30406932
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The role of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer: hope or hoax?
    Herzog TJ
    Ann Surg Oncol; 2012 Dec; 19(13):3998-4000. PubMed ID: 22833000
    [No Abstract]   [Full Text] [Related]  

  • 72. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis.
    Zhang G; Zhu Y; Liu C; Chao G; Cui R; Zhang Z
    J Ovarian Res; 2019 Apr; 12(1):33. PubMed ID: 30995948
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry.
    Helm CW; Richard SD; Pan J; Bartlett D; Goodman MD; Hoefer R; Lentz SS; Levine EA; Loggie BW; Metzinger DS; Miller B; Parker L; Spellman JE; Sugarbaker PH; Edwards RP; Rai SN
    Int J Gynecol Cancer; 2010 Jan; 20(1):61-9. PubMed ID: 20130504
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mininvasive Cytoreduction Surgery plus HIPEC for Epithelial Ovarian Cancer: A Systematic Review.
    Ronsini C; Pasanisi F; Greco P; Cobellis L; De Franciscis P; Cianci S
    Medicina (Kaunas); 2023 Feb; 59(3):. PubMed ID: 36984422
    [No Abstract]   [Full Text] [Related]  

  • 75. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
    Vaira M; Robella M; Mellano A; Sottile A; De Simone M
    Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.
    Cascales Campos P; Gil J; Parrilla P
    Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study.
    Lee YJ; Lee JY; Cho MS; Nam EJ; Kim SW; Kim S; Kim YT
    J Gynecol Oncol; 2019 Jan; 30(1):e3. PubMed ID: 30479087
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer.
    Ceelen WP; Van Nieuwenhove Y; Van Belle S; Denys H; Pattyn P
    Ann Surg Oncol; 2012 Jul; 19(7):2352-9. PubMed ID: 20039210
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer.
    Vergote I; Harter P; Chiva L
    Cancer; 2019 Dec; 125 Suppl 24():4594-4597. PubMed ID: 31967685
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Results of oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent ovarian granulosa cell tumors.
    Gouy S; Uzan C; Pautier P; Lhomme C; Duvillard P; Morice P
    Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):464-7. PubMed ID: 23915762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.